60 Degrees rises as FDA green lights Australian import of anti-malaria drug

60 Degrees Pharmaceuticals

11/02/2025 19:29

** Specialty pharma firm 60 Degrees Pharmaceuticals'
 SXTP.O  shares rise 5.6% to 63 cents in afternoon trade
    ** Company says the FDA does not object to co's plan to
import anti-malaria drug from Australia against any near-term
disruption in the U.S.
    ** Arakoda is an antimalarial drug for the prophylaxis of
malaria in patients aged 18 years and older in the U.S. 
    ** The drug is sold under the brand name Kodatef in
Australia 
    ** The drug is not approved for use in the U.S.
    ** SXTP plans to import a five-month supply of Kodatef while
increasing manufacturing of Arakoda over long term
    ** Co says the two products are identical in their dosing
regimens, mechanisms of action, safety and efficacy profiles,
and other clinical features 
    ** In the last 12 months, stock has fallen 80.2% 

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))